CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Willmott on Using Genetic Testing to Inform PARP Inhibitor Selection in Ovarian Cancer

onclive.com
 2021-07-29

Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results. Lyndsay Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results. Patients whose...

www.onclive.com

Comments / 0

Comments / 0